Incidence of intracranial hemorrhage in pediatric oncology patients
When children with cancer are treated with chemotherapy, they often require transfusions when their platelet counts are low. Platelet transfusions are provided prophylactically to prevent bleeding, particularly bleeding in the brain also known as intracranial hemorrhages (ICH).
Although previous studies have assessed risk factors for bleeding in adult cancer patients, few have focused on children. Adults and children differ with respect to the types of cancers they experience, the treatment they receive and potentially their likelihood of bleeding.
This project will assess how often children with cancer experience an ICH while they are receiving chemotherapy. The study will also assess if there are any identifiable risk factors, making these patients more likely to experience this complication. Finally, the patient's final outcome one month following the bleeding event will be determined.
Results of this study will provide an estimate of the incidence of ICH in pediatric oncology patients and attempt to link this event to relevant risk factors and hematologic lab values. This foundational information is required to generate hypotheses to be tested in future international collaborative studies. Future studies will investigate the vlaue of using other risk factors or a bleeding scale prior to ordering a platelet transfusion.
Although previous studies have assessed risk factors for bleeding in adult cancer patients, few have focused on children. Adults and children differ with respect to the types of cancers they experience, the treatment they receive and potentially their likelihood of bleeding.
This project will assess how often children with cancer experience an ICH while they are receiving chemotherapy. The study will also assess if there are any identifiable risk factors, making these patients more likely to experience this complication. Finally, the patient's final outcome one month following the bleeding event will be determined.
Results of this study will provide an estimate of the incidence of ICH in pediatric oncology patients and attempt to link this event to relevant risk factors and hematologic lab values. This foundational information is required to generate hypotheses to be tested in future international collaborative studies. Future studies will investigate the vlaue of using other risk factors or a bleeding scale prior to ordering a platelet transfusion.
Principal Investigator / Supervisor
WEBERT, Kathryn
Institution
Canadian Blood Services
Program
Small Project Funding Program
Province
Ontario
Total Amount Awarded
$15,000
Project Start Date
Project End Date